Silence Therapeutics plc Stock London S.E.
Stocks
GB0008433350
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| Market Cap | 434M 573M 512M 478M 816M 55.51B 824M 5.73B 2.24B 28.21B 2.15B 2.11B 90.72B | P/E 2026 * |
-17.9x | P/E 2027 * | -14.4x |
|---|---|---|---|---|---|
| Enterprise Value | 301M 397M 355M 331M 566M 38.48B 571M 3.97B 1.55B 19.55B 1.49B 1.46B 62.89B | EV / Sales 2026 * |
932x | EV / Sales 2027 * | 346x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-11-30 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-01-31 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2003-12-31 |
Tim McInerney
BRD | Director/Board Member | 65 | 2025-05-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.19% | -3.19% | +44.60% | +87.98% | 74.68B | |
| -15.86% | -16.16% | +2.68% | +50.90% | 58.7B | |
| -2.39% | -2.05% | +4.29% | +31.33% | 48.36B | |
| -6.35% | -8.63% | +293.39% | +651.28% | 43.05B | |
| +0.30% | -0.71% | +29.05% | +30.33% | 42.48B | |
| -3.82% | -2.41% | -0.27% | +101.36% | 41.39B | |
| -2.13% | +1.07% | +7.51% | +50.31% | 31.29B | |
| -3.35% | -4.95% | -13.38% | -17.22% | 23.93B | |
| -1.24% | -7.47% | -37.90% | +311.13% | 22.22B | |
| Average | -4.23% | -4.56% | +36.66% | +144.16% | 42.9B | |
| Weighted average by Cap. | -4.86% | -4.30% | +43.05% | +136.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 322K 426K 380K 355K 607K 41.27M 613K 4.26M 1.67M 20.97M 1.6M 1.57M 67.44M | 751K 992K 886K 826K 1.41M 96.05M 1.43M 9.92M 3.88M 48.81M 3.72M 3.64M 157M |
| Net income | -42.14M -55.68M -49.72M -46.39M -79.29M -5.39B -80.06M -557M -218M -2.74B -209M -205M -8.81B | -71.01M -93.84M -83.8M -78.17M -134M -9.09B -135M -939M -367M -4.62B -352M -345M -14.85B |
| Net Debt | -133M -176M -157M -147M -250M -17.03B -253M -1.76B -688M -8.66B -660M -646M -27.84B | -174M -230M -205M -192M -328M -22.27B -331M -2.3B -900M -11.32B -863M -845M -36.4B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
